[刺激性肠综合征的饮食疗法]
1Department of Internal Medicine, College of Medicine, Seoul National University, Seoul, Korea.
概括
刺激性肠综合征 (IBS) 可以通过像低FODMAP饮食这样的全方位饮食干预来有效管理. 谨慎的应用对于IBS患者至关重要,考虑到各种饮食方法.
科学领域:
- 胃肠病学 胃肠病学
- 临床营养学 临床营养学
背景情况:
- 刺激性肠综合征 (IBS) 显著影响生活质量和医疗保健.
- IBS的病理生理学是复杂的和多因素的.
- 饮食因素经常引发或加重IBS症状.
研究的目的:
- 审查关于IBS全方位饮食疗法的证据.
- 讨论在临床实践中实施饮食干预措施的考虑因素.
主要方法:
- 对IBS的全方位饮食疗法的文献综述.
- 临床指南和证据的分析.
主要成果:
- 低发酵性寡糖,分糖,单糖和多 (低FODMAP) 饮食是基于IBS的证据.
- 其他饮食方法,包括低粉和低糖饮食,已经被探索.
- 指南建议低FODMAP饮食,但建议谨慎使用.
结论:
- 整体饮食疗法对于管理IBS有价值.
- 个性化患者评估对于在IBS中成功进行饮食干预至关重要.
- 进一步的研究可能会澄清IBS管理的最佳饮食策略.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
236
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
236
Irritable Bowel Syndrome III: Medical and Nursing Management
117
Managing Irritable Bowel Syndrome (IBS) involves a multifaceted approach, including lifestyle modifications, dietary changes, and medication.
117
Drugs for Treatment of Diarrhea-Predominant IBS
117
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
117
Irritable Bowel Syndrome I: Introduction
203
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
203
Drugs for Treatment of Constipation-Predominant IBS
109
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
109
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
96
Irritable Bowel Syndrome II: Clinical Features and Diagnostic Evaluation
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
Irritable Bowel Syndrome (IBS) is classified into subtypes based on the predominant bowel habits as determined by the Bristol Stool Form Scale (BSFS). The subtypes are:
96


